Sickle Cell Disease Clinical Trials in Los Angeles, California

7 studies are recruiting for sickle cell disease in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Children's Hospital Los Angeles - Endocrinology, Los Angeles, California

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Children's Hospital Los Angeles - Endocrinology, Los Angeles, California

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Orthopaedic Institute for Children HTC, Los Angeles, California

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

4. Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

   This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD34 enrichment and T…

   Stage

   Phase 2

   Ages

   0 to 21

   Site

   University of California Los Angeles, Los Angeles, California

   Locations

   4 in total

   Run by

   New York Medical College

   See if you can join NCT02675959 on ClinicalTrials.gov

5. Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

   This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynam…

   Stage

   Phase 1

   Ages

   12 to 50

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   Kamau Therapeutics

   See if you can join NCT04819841 on ClinicalTrials.gov

6. Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

   This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will …

   Stage

   Phase 1

   Ages

   12 to 35

   Site

   University of California, Los Angeles, Los Angeles, California

   Locations

   2 in total

   Run by

   Mark Walters, MD

   See if you can join NCT04774536 on ClinicalTrials.gov

7. Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

   The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also s…

   Stage

   Not phased

   Ages

   16 to 30

   Site

   UCLA Mattel Children's Hospital Ronald Reagan Hospital, Los Angeles, California

   Locations

   14 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06374238 on ClinicalTrials.gov